Drugs / Bisacodyl
Bisacodyl
also known as
Dulcolax · Biolax · Bis · Bisacodilo · Bisacodyl 5 mg tablets · Bisacodyl component of halflytely · Bisacodyl ER · Biscodyl · +10 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HALFLYTELY | — | 2004-05-10 | fda.gov ↗ |
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07127237 | Sep 2025 → Feb 2026 overdue | — | Hospital de Clínicas Dr. Manuel Quintela | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02211911 | Feb → May 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02609607 | Jun 2016 → Nov 2018 | constipation disorder, multiple sclerosis | David Levinthal | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02123017 | Apr → Aug 2014 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01044394 | Jan 2010 → Jun 2011 | — | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 38 trials · 2 met primary | ||||||
| Phase 3 | NCT07668778 | Aug 2026 → Aug 2027 expected | cirrhosis of liver | Hospital do Divino Espírito Santo de Ponta Delgada | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01745835 | Jan → Aug 2013 | — | Seoul National University Hospital | Completed | Met primary |
| Phase 3 | NCT01655095 | Jul → Oct 2012 | polyp | Queen's University | Completed | No outcome recorded |
| Phase 3 | NCT01685853 | Apr 2011 → Mar 2012 | — | European Institute of Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00526097 | Sep 2007 → Jun 2009 | constipation disorder | Boehringer Ingelheim | Completed | Met primary |
| Phase 3 | NCT02211976 | Oct → Nov 2003 | constipation disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00164151 | Jun 2001 → May 2002 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00164164 | Aug 1999 → Jun 2000 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase 413 trials · 1 met primary | ||||||
| Phase 4 | NCT04129788 | Oct 2020 → Nov 2022 | constipation disorder | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT04132661 | Sep 2020 → Nov 2022 | constipation disorder | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT02761317 | May → Nov 2016 | — | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT02415569 | Jan → Oct 2015 | — | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT01853709 | May → Dec 2013 | — | Corporacion Parc Tauli | Unknown | No outcome recorded |
| Phase 4 | NCT02040285 | Feb → Jul 2012 | — | Azienda Policlinico Umberto I | Completed | No outcome recorded |
| Phase 4 | NCT01510977 | Nov 2011 → Feb 2013 | — | Asan Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01427296 | Sep 2011 → Mar 2014 | — | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01531140 | Nov 2010 → Nov 2011 | — | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT01509131 | Mar → Dec 2010 | — | Promefarm S.r.l. | Completed | No outcome recorded |
| Phase 4 | NCT01063049 | Feb 2010 → Feb 2011 | — | Gastroenterology Services, Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00857272 | Feb → May 2009 | — | Braintree Laboratories | Completed | Met primary |
| Phase 4 | NCT00278967 | Feb → Aug 2006 | — | Braintree Laboratories | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07328880 | Apr 2025 → Apr 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT07557173 | Jan 2024 → Jun 2026 overdue | — | Ospedale San Pio | Recruiting | No outcome recorded |
| — | NCT04903470 | Dec 2022 → Dec 2026 expected | outlet dysfunction constipation | The California Medical Innovations Institute, Inc. | Recruiting | No outcome recorded |
| — | NCT04033250 | Sep 2019 → Sep 2020 | — | Rambam Health Care Campus | Unknown | No outcome recorded |
| — | NCT03248726 | Jul 2017 → Sep 2019 | — | Taipei Medical University WanFang Hospital | Completed | No outcome recorded |
| — | NCT02383758 | Feb 2015 → Jan 2017 | autism spectrum disorder, bowel dysfunction | Emory University | Completed | No outcome recorded |
| — | NCT01452737 | Nov 2011 → May 2012 | — | University of British Columbia | Withdrawn | No outcome recorded |
| — | NCT01533688 | Oct 2011 → Oct 2016 | diabetes mellitus | University of Oklahoma | Completed | No outcome recorded |
| — | NCT01398020 | Jul 2011 → Sep 2012 | — | University of British Columbia | Completed | No outcome recorded |
| — | NCT01533090 | Apr → Nov 2010 | inflammatory bowel disease, malignant colon neoplasm, polyp of colon | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT01044212 | Nov 2009 → Feb 2011 | intestinal disorder | University of Rochester | Completed | No outcome recorded |
| Comparator or background therapy39 trials | ||||||
| Phase 1 | NCT05409157 Background | Jun → Oct 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01156129 Comparator | Sep 2010 → Jul 2012 | ileus | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT04238091 Comparator | Dec 2019 → Mar 2022 | alopecia areata, alopecia totalis, alopecia universalis | Lindsey Bordone | Withdrawn | No outcome recorded |
| Phase 2 | NCT01885104 Background | Apr → Sep 2013 | constipation disorder | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT01011426 Comparator | Apr 2009 → Jun 2012 | — | The Cooper Health System | Completed | No outcome recorded |
| Phase 3 | NCT05144295 Comparator | Jan → Aug 2022 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT03992365 Comparator | Jun → Oct 2019 | — | Universal Integrated Corp. | Completed | No outcome recorded |
| Phase 3 | NCT02976805 Background | Feb 2017 → Feb 2020 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Missed primary |
| Phase 3 | NCT02980562 Comparator | May → Sep 2015 | colon adenoma | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01982240 Background | Nov 2013 → Apr 2015 | constipation disorder | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01415687 Comparator | May → Dec 2011 | — | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT01073930 Comparator | May → Oct 2010 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01073943 Comparator | May → Oct 2010 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT07351357 Comparator | Jan 2026 → Aug 2027 expected | chronic renal failure syndrome | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06455813 Comparator | Oct 2024 → Jan 2027 expected | — | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03830489 Background | Feb → Oct 2019 | — | Hospital Universitario de Canarias | Completed | Missed primary |
| Phase 4 | NCT02977286 Background | Jan 2017 → Oct 2019 | constipation disorder | Tufts Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02547571 Comparator | Mar 2016 → Sep 2018 | — | Alan Barkun | Completed | No outcome recorded |
| Phase 4 | NCT02119000 Comparator | Aug 2015 → Jan 2020 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02386449 Comparator | Feb → Dec 2015 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01917773 Background | Aug 2013 → Jun 2014 | constipation disorder, intestinal motility disease | Indiana University | Completed | Missed primary |
| Phase 4 | NCT01887158 Comparator | Jul 2013 → Jun 2014 | intestinal cancer | Ospedale Santa Maria delle Croci | Completed | No outcome recorded |
| Phase 4 | NCT01773096 Background | May 2013 → May 2015 | constipation disorder | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 4 | NCT01865916 Comparator | Apr 2013 → Dec 2015 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT03279341 Comparator | Dec 2012 → Mar 2016 | constipation disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| Phase 4 | NCT01627171 Background | Sep 2012 → Dec 2013 | — | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 4 | NCT00953017 Comparator | Jul 2009 → May 2010 | — | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01879605 Comparator | Dec 2007 → Dec 2009 | constipation disorder, ileus | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00410215 Comparator | Feb 2006 → Jan 2008 | — | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00509327 Comparator | Nov 2004 → Feb 2007 | ileus | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT07674160 Comparator | Aug 2026 → May 2028 expected | — | Dalin Tzu Chi General Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05726344 Background | Feb → Dec 2023 | — | Hospital de Clínicas Dr. Manuel Quintela | Completed | No outcome recorded |
| — | NCT05723731 Background | Jan → Jul 2023 | constipation disorder | Air Force Military Medical University, China | Terminated | No outcome recorded |
| — | NCT05032794 Background | Oct 2021 → Aug 2022 | intestinal cancer | Parc Taulí Hospital Universitari | Completed | No outcome recorded |
| — | NCT03849196 Comparator | Jul 2017 → Jan 2018 | — | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT03226145 Comparator | Jul 2017 → Sep 2020 | constipation disorder, irritable bowel syndrome | University of Nottingham | Unknown | No outcome recorded |
| — | NCT03146052 Background | Mar → May 2017 | polyp | ASST Rhodense | Completed | Met primary |
| — | NCT02481219 Background | May 2015 → Jan 2016 | colorectal cancer | Medtronic - MITG | Completed | No outcome recorded |
| — | NCT01299779 Background | Jun 2010 → May 2012 | — | Thomas Jefferson University | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-03-01 | Boehringer Ingelheim | Carmen Marc Valvo, Designer and Cancer Survivor, Teams Up With Dulcolax® and the Colon Cancer Alliance to Make it Fashionable for Americans to Get Screened prnewswire.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bisacodyl | “All participants followed a standardized bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution administered in a split-dose regimen.” NCT07674160 ↗74“A Comparison of the Efficacy and Safety of Two Bowel Preparations: HalfLytely® (2L NuLYTELY and 20 mg Bisacodyl), and Visicol™ Prior To Colonoscopy.” NCT00164151 ↗ “The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc).” NCT04238091 ↗ “The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm.” NCT05726344 ↗ “The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet” NCT03830489 ↗ “4 liters of polyethylene glycol plus bisacodyl 12 mg administered as rescue bowel preparation before repeat colonoscopy.” NCT07557173 ↗ “Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.” NCT05723731 ↗ “Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.” NCT01398020 ↗ “15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses” NCT02123017 ↗ “Bisacodyl: two 5-mg tablets at 3 pm day prior” NCT01299779 ↗ “HalfLytely (2L NULYTELY + 20mg bisacodyl)” NCT00164164 ↗ |
| Known as | Biolax | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Bis | “In addition, oral bisacodyl (Bis) has been shown to reduce the volume of PEG needed for a bowel preparation with comparable efficacy.” PMID 27588943 ↗ Sep 2016 |
| Known as | Bisacodilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Bisacodyl 5 mg tablets | “Bisacodyl 5 mg tablets” NCT05144295 ↗ |
| Known as | Bisacodyl component of halflytely | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Bisacodyl ER | “take 3 tablets of Bisacodyl ER (15 mg) orally” NCT02119000 ↗ |
| Known as | Biscodyl | “Biscodyl 10 mg + Docusate sodium 100 mg (Minalax) 8 tablets” NCT07328880 ↗ |
| Known as | Correctol tablets, caplets | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Dulcodos | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Dulcolax | “with bisacodyl (Dulcolax) tablets 10 mg to placebo” NCT00526097 ↗ |
| Known as | Entrolax | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Evac-q-tabs | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Feen-a-mint tablets | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Lovoldyl (Bisacodyl) | “Lovoldyl (Bisacodyl)” NCT02040285 ↗ |
| Known as | Modane | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | NSC-755914 | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Sk-bisacodyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Known as | Theralax | ChEMBL registry synonym — accepted as the source's own label CHEMBL942 ↗ |
| Action | Activate | “It works at the level of the enteric nerves to stimulate colon motility.” NCT04903470 ↗ |
| Modality | Small molecule | — CHEMBL942 ↗ |
| Route | Oral | “Administered Orally” NCT00526097 ↗ |